title: Transduction of the IL2 gene into human acute leukemia cells: induction of tumor rejection without modifying cell proliferation and IL2 receptor expression.
abstract: BACKGROUND
  Previous studies have suggested that some of the limitations associated with the administration of high-dose exogenous interleukin 2 (IL2) may be overcome, at least partly, by cytokine gene transfer modalities. These findings have prompted investigations into whether human tumor cells may be transduced with the IL2 gene and whether tumor cell lines could be engineered to release IL2.
  
  
  OBJECTIVE
  The purpose of this study was to evaluate the possibility of inducing a productive transfer of the IL2 gene into human acute leukemia cells and to assess the phenotypic and proliferative changes generated in the engineered cells, as well as their tumorigenic potential in nude mice.
  
  
  METHODS
  Three retroviral vectors (DC/TK/IL2, DC/AD/R/IL2, and N2/CMV/IL2) carrying the IL2 gene were used to transduce three human leukemic cell lines: K562 and U937 (myeloid) and ST4 (lymphoid). Messenger RNA expression of the IL2 gene was analyzed by reverse transcriptase-polymerase chain reaction (RT-PCR) and productive IL2 release using a human IL2 assay and an enzyme-linked immunosorbent assay kit. The expression of the p55 (alpha) and p75 (beta) chains of the IL2 receptor were determined by RT-PCR and indirect immunofluorescence. The kinetics of in vitro growth and proliferation of parental and engineered cells were also measured. Parental and IL2 gene-transduced ST4 lymphoblasts were injected into immunosuppressed nude mice that had their tumors measured twice weekly.
  
  
  RESULTS
  The productive insertion of the IL2 gene was achieved in all three cell lines studied. The amounts of IL2 constitutively released by the engineered neoplastic cells ranged between 1 and 11 U/mL of IL2 produced from 10(6) cells in 72 hours. A fivefold increase in IL2 production was obtained in ST4 cells by further limiting dilution cloning of the bulk-infected cells. The stable integration of the IL2 gene did not modify the phenotype of the leukemic cells, the expression of the IL2 receptor alpha and beta chains and of several cytokine genes, or the kinetics of in vitro growth and proliferation. In nude mice injected with various IL2-producing ST4 clones, tumor growth associated inversely with the amounts of IL2 secreted by the leukemic cells.
  
  
  CONCLUSIONS
  The results of this study demonstrate that the IL2 gene can be productively transduced into human myeloid and lymphoid leukemic cells without modifying their phenotypic and proliferative properties and that this transduction leads to a reduced or abrogated in vivo tumorigenic potential.
authors.affiliation: Dipartimento di Scienze Biomediche ed Oncologia Umana, Sezione Clinica, University of Turin, Italy.
authors.forename: A
authors.initials: A
authors.lastname: Cignetti
authors.forename: A
authors.initials: A
authors.lastname: Guarini
authors.forename: A
authors.initials: A
authors.lastname: Carbone
authors.forename: M
authors.initials: M
authors.lastname: Forni
authors.forename: K
authors.initials: K
authors.lastname: Cronin
authors.forename: G
authors.initials: G
authors.lastname: Forni
authors.forename: B
authors.initials: B
authors.lastname: Gansbacher
authors.forename: R
authors.initials: R
authors.lastname: Foa
mesh_terms: D000208:Acute Disease; D000818:Animals; D002455:Cell Division / Q000235:genetics; D005260:Female; D015870:Gene Expression; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors; D006801:Humans; D007376:Interleukin-2 / Q000096:biosynthesis / Q000235:genetics*; D007938:Leukemia / Q000276:immunology / Q000628:therapy*; D051379:Mice; D008819:Mice, Nude; D008979:Moloney murine leukemia virus; D012333:RNA, Messenger / Q000096:biosynthesis; D015375:Receptors, Interleukin-2 / Q000235:genetics; D013997:Time Factors; D014407:Tumor Cells, Cultured
chemical_list: D007376:Interleukin-2; D012333:RNA, Messenger; D015375:Receptors, Interleukin-2